Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last CNY43.24 CNY
Change Today +2.65 / 6.53%
Volume 18.6M
As of 3:05 AM 05/27/15 All times are local (Market data is delayed by at least 15 minutes).

mayinglong pharmaceutical-a (600993) Snapshot

Open
CNY40.55
Previous Close
CNY40.59
Day High
CNY44.65
Day Low
CNY39.45
52 Week High
05/27/15 - CNY44.65
52 Week Low
06/4/14 - CNY15.05
Market Cap
14.3B
Average Volume 10 Days
12.6M
EPS TTM
CNY0.62
Shares Outstanding
331.6M
EX-Date
--
P/E TM
70.3x
Dividend
CNY0.04
Dividend Yield
0.40%
Current Stock Chart for MAYINGLONG PHARMACEUTICAL-A (600993)

Related News

No related news articles were found.

mayinglong pharmaceutical-a (600993) Related Businessweek News

No Related Businessweek News Found

mayinglong pharmaceutical-a (600993) Details

Mayinglong Pharmaceutical Group Co., Ltd. is engaged in the manufacture, wholesale, and retail of pharmaceutical products primarily in China. It offers hemorrhoid, gynecological, cough, skin, cosmeceutical, and other products, as well as drugstore and merchants varieties. The company provides its products in various dosage forms comprising ointments, suppositories, tablets, pastes and granules, and oral solutions. It also produces and distributes eye cream products under the Mayinglong BaBao brand name; and operates hospitals. The company was founded in 1582 and is based in Wuhan, China.

Founded in 1582

mayinglong pharmaceutical-a (600993) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

mayinglong pharmaceutical-a (600993) Key Developments

Mayinglong Pharmaceutical Group Co,.LTD Reports Earnings Results for 2014

Mayinglong Pharmaceutical Group Co,.LTD reported earnings results for 2014. For the period, the company reported basic earnings per share of CNY 0.61. Weighted average return on net assets was 13.49%.

Mayinglong Pharmaceutical Group Co,.Ltd Reports Earnings Results for the First Quarter of 2015

Mayinglong Pharmaceutical Group Co,.LTD reported earnings results for the first quarter of 2015. For the period, the company reported basic earnings per share of CNY 0.22. Weighted average return on net assets was 4.29%.

Mayinglong Pharmaceutical Group Co,.LTD, Board Meeting, Apr 23, 2015

Mayinglong Pharmaceutical Group Co,.LTD, Board Meeting, Apr 23, 2015. Agenda: To discuss and approve the issues including the scheme of profit distribution in 2014; to consider the annual report of 2014 and its abstract; and to consider the first quarter report of 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
600993:CH CNY43.24 CNY +2.65

600993 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 600993.
View Industry Companies
 

Industry Analysis

600993

Industry Average

Valuation 600993 Industry Range
Price/Earnings 66.0x
Price/Sales 8.3x
Price/Book 8.2x
Price/Cash Flow 65.9x
TEV/Sales 7.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MAYINGLONG PHARMACEUTICAL-A, please visit www.mayinglong.cn. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.